Skip to main content

Table 2 Incidence of adverse events per patient

From: Dose escalation results from a first-in-human, phase 1 study of glucocorticoid-induced TNF receptor–related protein agonist AMG 228 in patients with advanced solid tumors

 

All Patients (N = 30)

Patients with any treatment-emergent AE, n (%)

30 (100)

Patients with any treatment-emergent serious AE, n (%)

12 (40)

Patients with a grade 3 treatment-related AE, n (%)

0

Patients with a grade 4 treatment-related AE, n (%)

0

Patients with a grade 5 treatment-related AE, n (%)

1 (3)

Incidence of treatment-related AEs, n (%)

18 (60)

 Fatigue, all grades

4 (13)

  Grade 1

3 (10)

  Grade 2

1 (3)

 Infusion-related reaction, all grades

2 (7)

  Grade 1

2 (7)

 Pyrexia, all grades

2 (7)

  Grade 1

2 (7)

 Decreased appetite, all grades

2 (7)

  Grade 1

2 (7)

 Hypophosphataemia, all grades

2 (7)

  Grade 2

2 (7)

  1. AE adverse event
  2. *AEs occurring in in ≥5% of patients are shown